Moving low-risk myelodysplastic syndromes from humans to mice: is it truly that simple?

被引：0
|
作者：
Coriu, Daniel [1 ]
Stancioaica, Maria -Camelia [1 ]
机构：
[1] Carol Davila Univ Med & Pharm, Fundeni Clin Inst, Ctr Hematol & Bone Marrow Transplantat, Bucharest, Romania
来源：
HAEMATOLOGICA | 2024年 / 109卷 / 01期
关键词：
D O I：
10.3324/haematol.2023.283652
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：8 / 10
页数：3
相关论文
共 50 条
  • [21] Impact of growth factors in the regulation of apoptosis in low-risk myelodysplastic syndromes
    R. Tehranchi
    Medical Oncology, 2006, 23 (1) : 37 - 49
  • [22] Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies
    Molica, Matteo
    Rossi, Marco
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2024, 24 (04) : 233 - 241
  • [23] Cigarette smoking shortens the survival of patients with low-risk myelodysplastic syndromes
    Xiaomei Ma
    Rong Wang
    Naomi Galili
    Susan T. Mayne
    Sa A. Wang
    Herbert Yu
    Azra Raza
    Cancer Causes & Control, 2011, 22 : 623 - 629
  • [24] An accessible patient-derived xenograft model of low-risk myelodysplastic syndromes
    Teodorescu, Patric
    Pasca, Sergiu
    Choi, Inyoung
    Shams, Cynthia
    Dalton, W. Brian
    Gondek, Lukasz P.
    DeZern, Amy E.
    Ghiaur, Gabriel
    HAEMATOLOGICA, 2024, 109 (01) : 337 - 342
  • [25] The Management of Low-Risk Myelodysplastic Syndromes-Current Standards and Recent Advances
    Randall, Michael P.
    DeZern, Amy E.
    CANCER JOURNAL, 2023, 29 (03): : 152 - 159
  • [26] High-dose rHuEPO for the treatment of patients with low-risk myelodysplastic syndromes
    Latagliata, R.
    Oliva, E.
    Volpicelli, P.
    Napoleone, L.
    Carmosino, I.
    Breccia, M.
    Stefanizzi, C.
    Vincelli, I.
    Alati, C.
    Vozella, F.
    Nobile, F.
    Alimena, G.
    LEUKEMIA RESEARCH, 2009, 33 : S121 - S121
  • [27] Luspatercept: a candidate to dethrone erythropoietin in first line in low-risk myelodysplastic syndromes?
    Robert-Van Houtteghem, Tristan
    HEMATOLOGIE, 2023, 29 (05): : 269 - 271
  • [28] HEPCIDIN AND ERYTHROFERRONE (ERFE) ARE NOT CORRELATED IN THE ANEMIA OF LOW-RISK MYELODYSPLASTIC SYNDROMES (MDS)
    Redondo, S.
    Oarbeascoa, G.
    Moran Jimenez, M. J.
    Domingo, A.
    Munoz Linares, C.
    Moreno Carralero, M. I.
    Bellon, J. M.
    Del Campo Rincon, J. F.
    Diez-Martin, J. L.
    Font, P.
    HAEMATOLOGICA, 2018, 103 : 183 - 184
  • [29] Efficacy of growth factors compared to chemotherapy in low-risk myelodysplastic syndromes.
    Golshayan, A
    Fu, AZ
    Kattan, MW
    Brown, S
    Maciejewski, JP
    Sekeres, MA
    BLOOD, 2005, 106 (11) : 713A - 714A
  • [30] Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes
    Golshayan, Ali-Reza
    Jin, Tao
    Maciejewski, Jaroslaw
    Fu, Alex Z.
    Bershadsky, Boris
    Kattan, Michael W.
    Kalaycio, Matt E.
    Sekeres, Mikkael A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2007, 137 (02) : 125 - 132
12345